To hear about similar clinical trials, please enter your email below
Trial Title:
CKD-702 Plus Irinotecan in Gastric Cancer
NCT ID:
NCT05750290
Condition:
Gastric Cancer
Conditions: Official terms:
Stomach Neoplasms
Irinotecan
Study type:
Interventional
Study phase:
Phase 2
Overall status:
Recruiting
Study design:
Allocation:
N/A
Intervention model:
Single Group Assignment
Primary purpose:
Treatment
Masking:
None (Open Label)
Intervention:
Intervention type:
Drug
Intervention name:
CKD-702 in combination with irinotecan
Description:
CKD-702 and irinotecan will be intravenously administered every 2 weeks.
Arm group label:
CKD-702 in combination with irinotecan
Summary:
CKD-702 is a tetravalent bispecific IgG1 targeting hepatocyte growth factor receptor
(MET) and epidermal growth factor receptor (EGFR). The investigators will test a
hypothesis that CKD-702 may augment the efficacy of biweekly irinotecan as a 3L or later
therapy for gastric cancer overexpressing either MET or EGFR.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
- Failed 2 or more lines of chemotherapy
- Tumor overexpressing either MET or EGFR
- Measurable lesion
Exclusion Criteria:
- Prior treatment with anti-MET/EGFR bispecific antibody
Gender:
All
Minimum age:
19 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
National Cancer Center
Address:
City:
Goyang
Zip:
10408
Country:
Korea, Republic of
Status:
Recruiting
Contact:
Last name:
Hark K Kim, MD,PhD
Phone:
+82-31-920-2238
Email:
hkim@ncc.re.kr
Contact backup:
Last name:
Hyegyung Chang, RN
Phone:
+82-31-920-2233
Email:
jhk@ncc.re.kr
Start date:
December 1, 2022
Completion date:
December 31, 2025
Lead sponsor:
Agency:
National Cancer Center, Korea
Agency class:
Other
Source:
National Cancer Center, Korea
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05750290
